Eventide Asset Management LLC held its position in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,300 shares of the biopharmaceutical company’s stock at the close of the first quarter. Celgene Corporation makes up approximately 2.5% of Eventide Asset Management LLC’s portfolio, making the stock its 7th largest position. Eventide Asset Management LLC’s holdings in Celgene Corporation were worth $37,988,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. State Street Corp raised its holdings in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Celgene Corporation by 4.9% during the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Celgene Corporation by 4.4% during the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. raised its holdings in shares of Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Celgene Corporation by 4.3% during the 1st quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock worth $446,406,000 after buying an additional 147,263 shares in the last quarter. 79.43% of the stock is owned by institutional investors.

A number of equities analysts have recently commented on CELG shares. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $98.00 price target (up previously from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the stock a “buy” rating in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $147.31.

Shares of Celgene Corporation (NASDAQ CELG) traded down 0.89% on Friday, reaching $140.50. The company’s stock had a trading volume of 3,675,872 shares. The company’s 50 day moving average price is $134.31 and its 200 day moving average price is $126.68. The company has a market cap of $109.92 billion, a P/E ratio of 43.51 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $142.64.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the prior year, the business earned $1.44 EPS. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.

In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now owns 9,250 shares in the company, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. Insiders have sold a total of 263,011 shares of company stock worth $35,078,473 in the last quarter. Company insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/10/celgene-corporation-celg-is-eventide-asset-management-llcs-7th-largest-position.html.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.